| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DEFa3 |
| Uniprot No | P59666 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 39-94aa |
| 氨基酸序列 | DIPEVVVSLAWDESLAPKHPGSRKNMDCYCRIPACIAGERRYGTCIYQGRLWAFCC |
| 预测分子量 | 8.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于DEFa3(Defensin Alpha 3)重组蛋白的示例参考文献(注：部分内容为假设性示例，具体文献需通过学术数据库验证)：
---
1. **文献名称**: *"Recombinant Human DEFa3 Exhibits Broad-Spectrum Antimicrobial Activity Against Multidrug-Resistant Pathogens"*
**作者**: Smith J, et al.
**摘要**: 本研究成功在大肠杆菌中表达并纯化了重组人DEFa3蛋白，验证其对多种耐药细菌(如MRSA和铜绿假单胞菌)的体外抗菌活性，揭示了其通过破坏细胞膜发挥作用的机制。
2. **文献名称**: *"Engineering of DEFa3 as a Potential Therapeutic Agent for Inflammatory Bowel Disease"*
**作者**: Lee C, et al.
**摘要**: 通过哺乳动物细胞系统表达重组DEFa3.发现其可抑制肠道炎症模型中促炎因子(如TNF-α和IL-6)的释放，表明其在治疗炎症性肠病中的潜在应用价值。
3. **文献名称**: *"Optimization of DEFa3 Recombinant Production in Pichia pastoris and Its Immunomodulatory Effects"*
**作者**: Zhang R, et al.
**摘要**: 利用毕赤酵母高效表达DEFa3.优化发酵条件后产量显著提高。实验表明重组蛋白可激活巨噬细胞的吞噬功能，并增强先天免疫反应。
4. **文献名称**: *"Structural and Functional Characterization of DEFa3 Mutants for Enhanced Stability"*
**作者**: Gupta S, et al.
**摘要**: 通过定点突变改良DEFa3的热稳定性及蛋白酶抗性，晶体结构分析揭示突变对蛋白构象的影响，为开发长效抗菌药物提供理论基础。
---
**注意**：以上文献为示例性质，实际引用时请通过 **PubMed**、**Web of Science** 或 **Google Scholar** 检索真实文献(关键词：DEFa3/DEFA3 recombinant protein)。若需开放获取论文，可尝试在 **PLOS ONE** 或 **Nature Communications** 等期刊中查找。
DEFa3 recombinant protein is a synthetic version of the naturally occurring human alpha-defensin 3. a small cationic peptide belonging to the defensin family. Defensins are evolutionarily conserved components of the innate immune system, primarily known for their broad-spectrum antimicrobial activity against bacteria, fungi, and enveloped viruses. Alpha-defensins, including DEFa3. are typically produced by neutrophils and epithelial cells at mucosal surfaces, serving as a first-line defense against pathogens. They exert their antimicrobial effects by disrupting microbial membrane integrity through electrostatic interactions and pore formation. DEFa3 also modulates immune responses by recruiting immune cells and influencing cytokine production.
The recombinant form of DEFa3 is generated using genetic engineering techniques, often expressed in prokaryotic (e.g., E. coli) or eukaryotic systems to ensure proper folding and post-translational modifications. This allows large-scale production for research and potential therapeutic applications. Studies have explored its role in combating antibiotic-resistant infections, wound healing, and inflammatory diseases. Notably, DEFa3 has shown promise in targeting multidrug-resistant pathogens while demonstrating lower propensity to induce bacterial resistance compared to conventional antibiotics. Its immunomodulatory properties are also being investigated in cancer immunotherapy and autoimmune conditions. However, challenges remain in optimizing stability, delivery methods, and minimizing cytotoxicity to host cells. Current research focuses on structural optimization, hybrid peptide design, and nanoparticle-based delivery systems to enhance its clinical applicability. DEFa3 exemplifies the growing interest in host-derived antimicrobial peptides as templates for novel therapeutic agents in an era of increasing antimicrobial resistance.
×
